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Context: The classic androgen synthesis pathway proceeds via dehydroepiandrosterone, andros-
tenedione, and testosterone to 5a-dihydrotestosterone. However, 5a-dihydrotestosterone syn-
thesis can also be achieved by an alternative pathway originating from 17a-hydroxyprogesterone
(17OHP), which accumulates in congenital adrenal hyperplasia (CAH). Similarly, recent work has
highlighted androstenedione-derived 11-oxygenated 19-carbon steroids as active androgens, and
in CAH, androstenedione is generated directly from 17OHP. The exact contribution of alternative
pathway activity to androgen excess in CAH and its response to glucocorticoid (GC) therapy is
unknown.
Objective: We sought to quantify classic and alternative pathway-mediated androgen synthesis in
CAH, their diurnal variation, and their response to conventional GC therapy and modified-release
hydrocortisone.
Methods: We used urinary steroid metabolome profiling by gas chromatography–mass spec-
trometry for 24-hour steroid excretion analysis, studying the impact of conventional GCs (hydro-
cortisone, prednisolone, and dexamethasone) in 55 adults with CAH and 60 controls. We studied
diurnal variation in steroid excretion by comparing 8-hourly collections (23:00–7:00, 7:00–15:00, and
15:00–23:00) in 16 patients with CAH taking conventional GCs and during 6 months of treatment
with modified-release hydrocortisone, Chronocort.
Results: Patients with CAH taking conventional GCs showed low excretion of classic pathway
androgen metabolites but excess excretion of the alternative pathway signature metabolites
3a,5a-17-hydroxypregnanolone and 11b-hydroxyandrosterone. Chronocort reduced 17OHP and
alternative pathway metabolite excretion to near-normal levels more consistently than other GC
preparations.
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Conclusions: Alternative pathway-mediated androgen synthesis significantly contributes to
androgen excess in CAH. Chronocort therapy appears superior to conventional GC therapy in
controlling androgen synthesis via alternative pathways through attenuation of their major
substrate, 17OHP. (J Clin Endocrinol Metab 102: 1797–1806, 2017)
Disruption of glucocorticoid (GC) synthesis is thedefining feature of all variants of congenital adrenal
hyperplasia (CAH), including its most prevalent cause, 21-
hydroxylase deficiency (21OHD) (1). This enzymatic block
results inGCdeficiency,with the consequent loss of negative
feedback to the pituitary gland and hypothalamus, driving
both adrenocorticotropic hormone (ACTH)-mediated ad-
renal androgen excess and adrenal hyperplasia. Mineralo-
corticoid deficiency may also be seen in 21OHD but to a
variable degree dependent on mutation severity (2).
The classic pathway of androgen synthesis proceeds
through dehydroepiandrosterone (DHEA), androstene-
dione, and testosterone to themost potent activator of the
androgen receptor, 5a-dihydrotestosterone (DHT). The
substrate of 21-hydroxylase, 17a-hydroxyprogesterone
(17OHP), accumulates in CAH due to 21OHD, resulting
in enhanced conversion to androstenedione and active
androgens. However, 17OHP is also a substrate for an
alternative pathway to androgen biosynthesis, which
generates DHT without the need for DHEA, androste-
nedione, or testosterone as intermediates (3, 4). In this
pathway, 17OHP is converted by consecutive 5a-reductase
and 3a-hydroxysteroid dehydrogenase activity to 3a,5a-
17-hydroxypregnanolone (3a,5a-17HP) and then down-
stream toDHT (Fig. 1) (5). Accumulation of the alternative
pathway intermediate 3a,5a-17HP has been demonstrated
in untreated patients with CAH due to 21OHD (6), but its
relative contribution to excess androgen synthesis has not
yet been investigated. Furthermore, recent work has
highlighted the role of another androgen biosynthesis
pathway that converts androstenedione in several steps
to 11-keto-testosterone and 11-keto-dihydrotestosterone
(Fig. 1), steroids that have been shown to act as potent
androgen receptor agonists (7–11).
Conventional management strategies for CAH include
the use of both immediate-release hydrocortisone and
longer-acting synthetic GC preparations, sometimes pre-
scribed in a reverse circadian pattern (1). These preparations
fail to mimic the normal diurnal profile of cortisol secretion
and therefore do not prevent the early morning surge of
ACTH that is the major driver of adrenal-mediated an-
drogen excess in CAH. As a consequence, the current
management of patients with CAH is complicated by the
need to strike a balance between sufficient control of en-
dogenous androgen excess and potential excess exposure to
exogenous GCs (12). A modified-release and delayed-
release GC preparation, Chronocort, has recently been
developed and shown to approximate the physiological
diurnal rhythm of cortisol release due to delayed release,
with peak levels during the earlymorning hours after intake
at bedtime (13, 14). The relative impact of both conven-
tional GC preparations and Chronocort on androgen
synthesis by classic and alternative pathways is not known.
In this study, we sought to quantify the diurnal con-
tribution of alternative pathway androgen synthesis to
androgen excess in CAH by assessing the excreted uri-
nary steroid metabolome of patients with 21OHD. We
investigated patients receiving conventional GC therapy
and patients treated with the modified-release hydro-
cortisone preparation Chronocort in comparison with
healthy controls with intact diurnal secretion of cortisol.
Patients and Methods
Patients
Alternative pathway androgen synthesis in patients with
CAH managed with conventional GC therapy was quantified
by analysis of 24-hour urinary steroid metabolite excretion in
55 adult patients with 21OHD, recruited from 2 specialist
centers, Birmingham and Munich, and 60 sex- and age-matched
controls, recruited fromBirmingham. In all participating patients,
the diagnosis of 21OHD had previously been confirmed fol-
lowinggenetic testing as part of their routine clinical care. Control
participants were healthy individuals without chronic disease
aged 18 to 80 years. None were taking oral contraceptives,
hormone replacement therapy other than corticosteroid re-
placement, or other medications known to alter steroid hormone
synthesis and/or metabolism at the time of urine collection.
A summary of patient and control characteristics is provided in
Table 1. Most of the 21OHD group was managed with pred-
nisolone (49%, n=27;median daily dose, 7.5mg; range, 5–15mg)
and the remainder with either hydrocortisone (24%, n = 13;
median daily dose, 30 mg; range, 20–37.5 mg) or dexamethasone
(27%,n=15;mediandaily dose, 0.5mg; range, 0.25–1.00mg).All
patients with salt-wasting CAH and some with simple-virilizing
CAH received additional mineralocorticoid replacement; daily
fludrocortisone doses ranged between 100 and 300 mg.
The impact of the modified-release hydrocortisone prepa-
ration Chronocort on alternative pathway synthesis was
assessed in a subgroup consisting of 16 patients with 21OHD.
All were enrolled in an open-label phase 2 study at the Na-
tional Institutes of Health Clinical Centre (clinicaltrials.gov,
NCT01735617) (14). Patients were maintained on twice-daily
Chronocort therapy for 6 months with dose adjustment used
based on clinical symptoms and serum biochemistry. Median
daily Chronocort dose at 6months was 27.5 (range, 15–40) mg.
Urinary steroid metabolite excretion was measured at baseline,
at day 4 of Chronocort therapy, and after 6 months of treat-
ment. Three 8-hour urine samples were collected within each of
these three 24-hour periods and were timed to reflect either
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night (23:00–07:00), morning (07:00–15:00), or evening
(15:00–23:00) periods. Steroid excretion in the 8-hourly urine
collection was compared with that of 12 healthy control par-
ticipants (median age, 32.9 years) who also provided three
8-hour urine collections with similar timing to reflect night,
morning, or evening periods. All participants provided in-
formed written consent. Ethical approval for the collection of
baseline data was provided by the South Birmingham Research
Ethics Committee for healthy controls and by West Midlands
Multicentre Research Ethics Committee and the University
Hospital Ethics Committee Munich for conventionally man-
aged patients with CAH. Phase 2 study approval for the
Chronocort-treated patients with CAH was provided by the
Eunice Kennedy Shriver National Institute of Child Health
and Human Development Institutional Review Board at the
National Institutes of Health.
Urinary steroid hormone analysis
Analysis of urinary excretion of steroid hormonemetabolites
was undertaken by quantitative gas chromatography–mass
spectrometry in selected ion-monitoring analysis mode as de-
scribed previously (7). Supplemental Table 1 summarizes the
steroid metabolites relevant to this study.
The 21-hydroxylase enzyme, CYP21A2, catalyzes the con-
version of 17OHP to the cortisol precursor 11-deoxycortisol.
The metabolic impact of 21OHD was thus assessed through
analysis of tetrahydro-11-deoxycortisol, the metabolite of the
CYP21A2 product 11-deoxycortisol, and the 17OHP metab-
olites 17HP and pregnanetriol, as well as pregnanetriolone
(PTONE). PTONE is the metabolite of 21-deoxycortisol, which
is generated from 17OHP by CYP11B1 and only produced in
appreciable amounts in the absence of 21-hydroxylase activity
(i.e., in 21OHD).
Classic androgen pathway activity was measured by quanti-
fication of themajor androgenmetabolites androsterone (An) and
etiocholanolone (Et). Activation of the alternative pathway to
DHT was assessed through quantification of its signature me-
tabolite, 3a,5a-17HP. Although androstenedione and testoster-
one both feed into An and Et, the most potent androgen, DHT, is
only represented in the 5a-reduced androgen metabolite An.
Thus, the Et pool is only enhanced by classic androgen pathway
activity, whereas the An pool increases with DHT synthesis via
both the classic and alternative pathways. We therefore used the
ratio 3a5a-17HP/An as an estimate of the proportional contri-
bution of the alternative pathway to androgen synthesis.
19-Carbon androgens oxygenated at position C-11 have
been shown to be produced by the adrenal glands, and 11-keto-
testosterone and 11-keto-DHT have been shown to activate the
androgen receptor (7, 10). Therefore, we measured the con-
centration of the major metabolite of urinary 11-oxy-C19 ste-
roid metabolites, 11b-hydroxyandrosterone (11b-OH-An).
Figure 1. Schematic overview of steroidogenesis. The graph depicts steroidogenesis, including the classic androgen synthesis pathway (shaded in
dark gray) and the 2 alternative androgen synthesis pathways (shaded in light gray; top, 11-oxygenated 19-carbon steroids; bottom, alternative
pathway to DHT). 3a,5a-17HP is labeled by its alternative full name, 17-OH-allopregnanolone.
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Statistical analysis
Data are presented as median and interquartile range unless
otherwise stated. Analyses were undertaken using the non-
parametric Mann-Whitney and Kruskal-Wallis with post hoc
Dunn tests for unpaired analyses. Paired data were analyzed
using the nonparametric Wilcoxon test with Bonferroni cor-
rection applied for repeated analyses. Statistical analyses were
undertaken using SPSS Statistics 21 (SPSS, Inc., Chicago, IL) and
P values ,0.05 were considered statistically significant. All
P values were 2-sided.
Results
24-Hour steroid metabolite excretion in patients
with CAH receiving conventional GC therapy
As expected, the excretion of the 17OHP metabolites
17HP and pregnanetriol and the 21-deoxycortisol me-
tabolite PTONEwere significantly increased in CAH (P,
0.001), indicative of impaired 21-hydroxylase activity.
Conversely, the product of 21-hydroxylase activity, the
11-deoxycortisol metabolite tetrahydro-11-deoxycortisol,
was significantly lower (P, 0.001) in patients with CAH
than in control participants [Figs. 2(A) and 2(B)].
The urinary excretion of the sum of the major androgen
metabolitesAn andEtwas significantly lower in patientswith
CAH managed with conventional GC therapy than in sex-
and age-matched control participants [Fig. 2(C); P, 0.001].
Conversely, the signature metabolite of the alternative
pathway to DHT synthesis, 3a5a-17HP, was significantly
increased in patients with CAH [Fig. 2(D); P , 0.001]. The
ratio of 3a,5a-17HP to An was calculated to quantify the
contribution of the alternative pathway to total synthesis of
5a-reduced androgens, including DHT. This ratio was sig-
nificantly increased inpatientswithCAH,whereas alternative
pathway activity in the controls was negligible [P , 0.001;
Fig. 2(E)]. The excretion of the major metabolite of
11-oxygenated 19-carbon steroids, 11b-OH-An, appeared
similar to that in controls, with broad interindividual
variability in excretion amounts [Fig. 2(F)]. The pattern
of changes remained similarwhen carrying out sex-specific
subgroup analyses (Supplemental Fig. 1), which also
revealed higher excretion of the metabolites of 17OHP
[Supplemental Fig. 1(A)] and classic and alternative
pathway metabolites [Supplemental Fig. 1(C)–1(F)] in
male controls compared with female controls, whereas
no significant difference was observed betweenmale and
female patients with CAH.
Diurnal variation in steroid excretion in patients
with CAH receiving conventional GC therapy
Diurnal excretion analysis in urines collected in
8-hour intervals reflecting night (23:00–07:00), morn-
ing (7:00–15:00), and evening (15:00–23:00) showed a
similar picture to the 24-hour urine analysis when
comparing patients with CAH (n = 16; 4 of whom were
managed with hydrocortisone, 7 with prednisolone, and
5 with dexamethasone) to control participants (n = 12),
with lower classic pathway but higher excretion of the
signature metabolite of the alternative pathway to DHT
in patients with CAH (Fig. 3).
Healthy control participants showed significant di-
urnal variability of the metabolites of 17OHP and the
classic and alternative androgen pathways (Fig. 3), with
lowest excretion during nighttime. By contrast, this di-
urnal excretion pattern was lost in patients with CAH
receiving conventional GC therapy.
Differential impact of conventional GC preparations
on steroid excretion
To assess the effect of distinct conventional GC
therapies on androgen synthesis, we compared urinary
Table 1. Demographic Data for Patients With CAHManagedWith Conventional GC Treatment or Chronocort
and for Healthy Matched Control Participants
Characteristic
CAH Patients Taking
Conventional GC
Therapy (n = 55)
Control Cohort
(n = 60)
Chronocort-Treated Patients
With CAH (n = 16)
Control Cohort
(n = 12)
Male/female, n/n 28/27 32/28 8/8 12/0
Age, median (range), y 31 (19–49) 26 (20–48) 24 (18–60) 28.5 (22–60)
CAH phenotype, n (%)
Salt-wasting 41 (74.5) NA 12 (75) NA
Simple virilizing 14 (25.5) NA 4 (25) NA
GC preparation, n (%)
Hydrocortisone 13 (24) NA 3 (19) NA
Prednisolone 27 (49) NA 8 (50)a NA
Dexamethasone 15 (27) NA 5 (31) NA
For Chronocort-treated patients, their conventional GC medication prior to commencing Chronocort therapy is shown.
Abbreviation: NA, not applicable.
aOne patient received a combined hydrocortisone and prednisolone preparation prior to commencing Chronocort therapy and has been included in the
prednisolone group.
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steroid metabolite excretion in patients with CAH
managed with hydrocortisone (n = 13), prednisolone (n =
27), and dexamethasone (n = 15); all had been on stable
treatment for at least 6 months. This revealed that
hydrocortisone-treated patients with CAH had signifi-
cantly higher excretion of 17OHP metabolites, the sum of
the androgen metabolites An + Et and also the major
adrenal androgen metabolite 11b-OH-An, in comparison
with dexamethasone-treated patients, with prednisolone-
treated patients in an intermediate position (Supplemental
Fig. 2). Similarly, hydrocortisone therapy appeared
associated with the highest excretion of the alternative
pathway metabolite 3a,5a-17HP, but this difference
was not statistically significant due to high interindi-
vidual variability.
Diurnal steroid excretion during modified-release
hydrocortisone treatment
We assessed urinary steroid excretion in 16 patients
with CAH at baseline (i.e., taking conventional GC
treatment) and during treatment with modified-release
hydrocortisone, with diurnal urine collections in 8-hourly
intervals. This was carried out on 3 occasions: at baseline
when still receiving conventional GC therapy, shortly
after initiation of Chronocort treatment, day 4, and after
6 months of continuous treatment with Chronocort.
The analysis of the total 24-hour urine excretion
revealed a significant reduction in the combined excretion
of the markers of impaired 21-hydroxylase activity, the
sum of 17OHP metabolites 17HP, pregnanetriol, and
the 21-deoxycortisol metabolite PTONE, both after
4 days and 6 months of Chronocort treatment (all P ,
0.05) (Fig. 4),] with lower excretion amounts than ob-
served in patients treated with any other GC preparation
(Fig. 5). Total classic pathway androgen metabolite
excretion, An + Et, and excretion of the alternative
androgen pathway metabolite 3a5a-17HP significantly
decreased after Chronocort treatment to lower levels
than observed with any other GC preparation (Figs. 4
and 5). The excretion of 11b-OH-An also appeared to
decrease, albeit not significantly (Fig. 4). Attenuation
of 11-oxygenated 19-carbon androgen synthesis in
Chronocort-treated patients was at least similar to dexa-
methasone or prednisolone treatment and superior to the
effects of hydrocortisone treatment (Fig. 5). Of note,
24-hour urinary excretion of 11-hydroxy-etiocholanolone
and 11-oxo-etiocholanolone, which are exclusive GC
metabolites (15) and therefore reflective of the amount of
Figure 2. The 24-hour urinary steroid excretion in 55 patients with CAH and 60 healthy sex- and age-matched controls. For explanation of steroid
metabolite abbreviations, see Table 1. (A) 17OHP metabolites. (B) 11-deoxycortisol metabolite. (C) Sum of active androgen metabolites. (D) Signature
alternative pathway metabolite. (E) Ratio of alternative pathway/total 5a-reduced androgen metabolites. (F) Major 11-oxygenated androgen pathway
metabolite. Data are shown as mg/24 hours and presented as box-and-whisker plots to represent median, interquartile range (box), and 5th and
95th percentiles (whiskers). Urinary excretion of 3a5a-17HP available for 38 of the total CAH cohort. Analyses were undertaken using the Mann-
Whitney test. ***P # 0.001 for CAH vs controls. PT, pregnanetriol; THS, tetrahydro-11-deoxycortisol.
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exogenous cortisol, showed a higher excretion in patients
treated with conventional hydrocortisone than in patients
taking Chronocort.
The effect of 6 months of Chronocort therapy on the
diurnal rhythm of urinary steroid excretion in patients
with CAH is shown in Supplemental Fig. 3. There was
less variability seen across the three 8-hour periods in the
excretion of the metabolites of CYP21A2 following
Chronocort than prior to its initiation. Notably, the early
morning surge (nighttime period, 23:00–7:00) in the
activation of classic and alternative androgen pathway
synthesis appeared diminished following Chronocort
therapy [Supplemental Fig. 3(C)–3(F)].
Discussion
In this study, employing 24-hour urinary steroid metabolome
profiling, we could show that alternative pathway an-
drogen synthesis contributes significantly to andro-
gen excess in patients with CAH receiving chronic GC
therapy, both via the 11-oxygenated 19-carbon an-
drogen pathway and via DHT synthesis from 17OHP.
In addition, we have identified the differential impact
of conventional GC therapies and treatment with modified-
release hydrocortisone (Chronocort) on steroid excretion
in CAH, including their effects on alternative pathway
androgen synthesis—namely, the alternative “backdoor”
pathway to DHT and the 11-oxygenated C19 steroid
pathway.
Elements of the alternative “backdoor” pathway to
DHT were first described by Wilson et al. (5), reporting
the synthesis of 5a-androstanediol from 17OHP, with
3a,5a-17HP as the intermediate in the fetal testis of
the tammar wallaby pouch young. They hypothesized
that this pathway could extend to the conversion of
5a-androstanediol to DHT, thereby achieving active
androgen synthesis without the classic pathway inter-
mediates DHEA, androstenedione, and testosterone.
This led Auchus (3) to coin the term backdoor pathway
for this alternative pathway to DHT synthesis. They later
Figure 3. Eight-hourly diurnal urinary steroid metabolite excretion in 16 patients with CAH due to 21OHD and 12 healthy controls. (A) 17OHP
metabolites. (B) 11-deoxycortisol metabolite. (C) Sum of active androgen metabolites. (D) Signature alternative pathway metabolite. (E) Ratio of
alternative pathway/total 5a-reduced androgen metabolites. (F) Major 11-oxygenated androgen pathway metabolite. Data are shown for night
(23:00–07:00; dark gray), morning (07:00–15:00; white), and evening (15:00–23:00; light gray) time periods. Excretion of the major androgen
metabolites An + Et is shown for male patients with CAH (n = 8) and matched healthy controls (n = 12). Box-and-whisker plots represent
median, interquartile range (box), and 5th and 95th percentiles (whiskers). Comparisons were drawn within CAH and control groups with
analyses undertaken using the Friedman test, which was applied to the patients with CAH and the control participants separately. *P # 0.05 for
comparison of steroid excretion during different 8-hour periods. ***P # 0.001. PT, pregnanetriol; THS, tetrahydro-11-deoxycortisol.
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showed that the final step to DHT can indeed take place
in the gonads of the brushtail possum, the tammar
wallaby, and the short-tail opossum (16–18). Arlt et al.
(4) were the first to suggest the relevance of the alternative
pathway to DHT in humans, as an explanation for the
virilization of newborn girls affected by CAH, using the
example of CAH due to P450 oxidoreductase deficiency,
which results in disruption of the classic androgen
pathway. Although that work focused on the role of the
alternative pathway in prenatal life, they postulated that
synthesis of DHT via the alternative pathway is likely to
occur or increase, respectively, if there is an increase in
either the availability of its substrate 17OHP or the ac-
tivity of 5a-reductase type 1 activity, which catalyzes the
first step of the alternative pathway. Both progesterone
and 17OHP are efficient substrates for the 5a-reductase
activity of SRD5A1 (19), and both these steroids accu-
mulate in CAH with impaired 21-hydroxylase activity.
Homma et al. (20) showed increased urinary excretion
of the alternative pathway intermediate 3a,5a-17HP in
patients with CAH due to P450 oxidoreductase de-
ficiency; P450 oxidoreductase serves as the electron donor
enzyme to 21-hydroxylase, and therefore its disruption
results in impaired 21-hydroxylase activity. Subsequently,
Kamrath et al. (6) demonstrated increased 3a,5a-17HP in
newly diagnosed and hence untreated patients with CAH
due to 21OHD aged 1 day to 25 years, noting the highest
excretion amounts in the neonatal period. In this study
investigating the steroid metabolome in adult patients
with CAH taking established GC therapy, we found that
although classic androgen pathway activity was signifi-
cantly reduced, there was significantly increased excretion
of 3a,5a-17HP, indicating an increased relative contri-
bution of alternative androgen pathwayDHT synthesis to
androgen excess in CAHalso in adulthood and in patients
receiving regular GC treatment.
We also found increased excretion of 11b-OH-An, the
major metabolite of 11-oxygenated 19-carbon andro-
gens. Of note, Kamrath et al. (6) also showed significantly
increased excretion of 11b-OH-An in untreated patients
with CAH. However, at the time, they considered 11b-
OH-An a classic pathway metabolite, but in fact this
steroid represents the major metabolite of 11b-hydroxy-
androstenedione and other 11-oxygenated 19-carbon
Figure 4. Effect of Chronocort treatment on 24-hour urinary steroid metabolite excretion in patients with CAH due to 21OHD. (A) 17OHP
metabolites. (B) 11-deoxycortisol metabolite. (C) Sum of active androgen metabolites. (D) Signature alternative pathway metabolite. (E) Ratio of
alternative pathway/total 5a-reduced androgen metabolites. (F) Major 11-oxygenated androgen pathway metabolite. Results are shown for
patients with CAH at baseline taking conventional GC therapy prior to commencing Chronocort (BL; n = 16), at day 4 of Chronocort treatment
(D4; n = 16), and after 6 months of Chronocort treatment (M6; n = 15). Box-and-whisker plots represent median, interquartile range (box), and
5th and 95th percentiles (whiskers). Analyses were undertaken using repeated Wilcoxon tests with Bonferroni correction to compare between
matched patients with CAH. *P # 0.05. PT, pregnanetriol; THS, tetrahydro-11-deoxycortisol.
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androgens (15), effectively the second alternative path-
way to the synthesis of active androgens. Its end products,
11-keto-testosterone and 11-keto-DHT, have shown
similar androgenic activity to testosterone and DHT
(7–10). In a very recent publication, serum metabolome
profiling by tandem mass spectrometry demonstrated
3- to 4-fold increased circulating concentrations of
11b-hydroxy-androstenedione, 11-keto-androstenedione,
11b-hydroxy-testosterone, and 11-keto-testosterone in
patients with 21OHD (21). However, this was done in a
cross-sectional cohort of patients with CAH with no de-
tailed data on GC therapy available.
In our study, conventional GC therapy appeared to
control the activity of the alternative androgen synthesis
pathways less efficiently than classic pathway synthesis.
The latter we even found to be significantly suppressed in
patients with CAH, below the levels observed in healthy
sex- and age-matched controls, indicative of relative GC
overtreatment that is frequently observed in adult patients
with CAH (22). Studying the diurnal variation of steroid
excretion in our patients, we observed that the increased
excretion of the alternative pathway metabolites 3a,5a-
17HP and 11b-OH-An is most likely consequent to the
early morning surge in ACTH, which is unopposed in
patients with CAH taking conventional GC therapy.
Bycontrast,we found thatChronocort, amodified-release
hydrocortisone preparation, exerted much improved
control of alternative pathway-mediated androgen ex-
cess. Chronocort has been shown to yield cortisol
delivery mimicking physiological cortisol secretion (13),
resulting in significant normalization of circulating
17OHP and androstenedione levels in a previously
published phase 2 study in patients with CAH (14).
This effect was almost more impressively visible when
studying the urines of this cohort of 16 patients in our
study, with close to normalization of 17OHP metabolite
Figure 5. Urinary steroid excretion in 60 healthy controls and patients with CAH treated with Chronocort (n = 16), conventional immediate-
release hydrocortisone (n = 13), prednisolone (n = 27), or dexamethasone (n = 15). (A) Sum of active androgen metabolites. (B) Signature
alternative pathway metabolite. (C) 11b-hydroxyandrosterone, the major metabolite of the 11-oxygenated androgen pathway. (D) Sum of 17OHP
metabolites. (E) Glucocorticoid metabolite 11-hydroxy-etiocholanolone. (F) Glucocorticoid metabolite 11-oxo-etiocholanolone. Urinary excretion of
3a5a-17HP available for 54 of the total CAH cohort; 16 on Chronocort, 11 on conventional hydrocortisone, 21 on prednisolone, and 6 on
dexamethasone. GC treatment was stable for at least 6 months at the time of 24-hour urine collection. Box-and-whisker plots represent median,
interquartile range (box), and 5th and 95th percentiles (whiskers). Analyses were undertaken using the Kruskal-Wallis test with post hoc Dunn.
*P # 0.05, ***P # 0.001. PT, pregnanetriol; THS, tetrahydro-11-deoxycortisol.
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excretion in Chronocort-treated patients. Conventional
GC treatment never normalizes 17OHP secretion, and if
present, this would be considered an indicator of sig-
nificant over-replacement. However, near-normal di-
urnal provision of cortisol by Chronocort exerted
superior control of 17OHP secretion and thereby also of
both alternative androgen pathways driving androgen
excess in CAH, which are both fed by the conversion of
17OHP, either to 11-oxygenated 19-carbons steroids or
to 3a,5a-17HP and further downstream to DHT via the
“backdoor pathway.” An alternative modified-release
formulation of hydrocortisone, Plenadren, has immediate-
and delayed-release actions but is licensed for use in ad-
renal insufficiency, where it is taken first thing in the
morning as a once-daily medication (23), and was not
studied here. In the only study to our knowledge to report
the use of Plenadren in CAH, 6 patients with CAH were
included in an open-label trial of Plenadren where body
mass index, hemoglobin A1c, and quality of life were
measured but androgens were not reported (24).
Importantly, in our study, the analysis of the exclusive
cortisol metabolites 11b-hydroxy-etiocholanolone and
11-oxo-etiocholanolone (15) clearly indicated a higher
excretion in the patients on conventional hydrocortisone
treatment than in those treated with Chronocort, the
modified-release hydrocortisone preparation. This means
that the absolute amount of bioavailable cortisol was
actually lower in Chronocort-treated patients with CAH,
supporting the assumption that it was not the total
amount of GC but the improved diurnal delivery of
cortisol by Chronocort, and therefore the better control
of the early morning ACTH and steroid surge, that results
in the superior control of excess 17OHP and androgen
production.
A limitation of our study was the fact the CAH patient
groups receiving the 3 conventional GC preparations
(hydrocortisone, prednisolone, and dexamethasone)
were not matched for biochemical control at baseline and
were studied cross-sectionally and not during a controlled
crossover study. However, they were a cohort of con-
siderable size recruited from 2 large specialist centers,
which ensures a relative homogenization of clinical
presentation. An advantage of our study was the in-
clusion of adult patients only, which allowed us to dissect
androgen production in detail.
In conclusion, we have identified significant alterna-
tive androgen synthesis pathway activity in adult patients
with CAH taking conventional GC therapy that persists
despite suppression of classic pathway androgen pro-
duction by relative GC overtreatment. However, we
found that the modified-release hydrocortisone prepa-
ration Chronocort results in superior control of alter-
native pathway androgen production, most likely by
reducing the early morning surge in excess 17OHP,
which in CAH represents the major substrate for both
the alternative androgen pathway to DHT and the
11-oxygenated androgen pathway.
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